New markers such as cytokeratin 19 (CYFRA 21-1), mucins, tumor markers2 pyruvate-kinase (TuM2 PK), and metalloproteinase-7 (MMP-7) have helped to diagnose cholangiocarcinoma.[26] The present study reveals that patients with BTI have increased risk of biliary tract cancer (aHR: 24.45; 95% CI: 9.20–65.02) but BTI patients with gallbladder inflammation had no increased risk (aHR: 3.40; 95% CI: 0.65–17.67). Here, KRT19 is linked to cholangiocarcinoma.